Ozempic's Impact: Investors Urged to Short Junk-Food Stocks
British bank Barclays is advising investors to short stocks of companies targeted by the weight-loss drug industry, including junk-food and cigarette companies, due to the potential impact and uptake of drugs like Ozempic and Wegovy. These GLP-1 medications, used to treat type 2 diabetes and obesity, mimic a hormone that curbs appetite and aids weight-loss. The popularity of these drugs is expected to disrupt industries such as packaged foods, reflected in a decline in stock prices. However, companies like American pharmacy chain CVS Health and United Airlines could benefit indirectly from the growing weight-loss medication industry. Novo Nordisk, the manufacturer of these drugs, has seen a meteoric rise in recent years and briefly became Europe's most valuable company.